NinePointTwo Capital’s PTC Therapeutics PTCT Stock Holding History

NinePointTwo Capital’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,611	Closed	-$214K	–	297
2022 Q4	$214K	Buy	+5,611	New	+$233K	0.09%	101

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

NinePointTwo Capital's PTCT Position: Q1 2023 in Review

NinePointTwo Capital sold out of PTC Therapeutics (PTCT) in Q1 2023, closing a stake of 5,611 shares — an estimated $214K sold.

NinePointTwo Capital first reported a position in PTCT in Q4 2022 and held it in 1 quarter. The position peaked at $214K in Q4 2022. 202 funds tracked by Wall St. Rank hold PTCT as of Q1 2023.

NinePointTwo Capital reported no remaining PTC Therapeutics position as of Q1 2023 after selling out during the quarter.
NinePointTwo Capital sold 5,611 PTC Therapeutics shares in Q1 2023, an estimated $214K.
NinePointTwo Capital first reported a position in PTC Therapeutics in Q4 2022 and held it in 1 quarter.
NinePointTwo Capital's PTC Therapeutics position peaked at $214K in Q4 2022.
202 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2023.

Based on NinePointTwo Capital's 13F filing for Q1 2023, filed 15 May 2023.